Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable antipsychotic
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1744-859X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable antipsychotic ; volume:22 ; number:1 ; day:17 ; month:1 ; year:2023 ; pages:1-8 ; date:12.2023
Annals of general psychiatry ; 22, Heft 1 (17.1.2023), 1-8, 12.2023
- Urheber
-
Vita, Antonio
Fagiolini, Andrea
Maina, Giuseppe
Mencacci, Claudio
Spina, Edoardo
Galderisi, Silvana
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12991-022-00430-1
- URN
-
urn:nbn:de:101:1-2023032509380911213412
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Vita, Antonio
- Fagiolini, Andrea
- Maina, Giuseppe
- Mencacci, Claudio
- Spina, Edoardo
- Galderisi, Silvana
- SpringerLink (Online service)
Ähnliche Objekte (12)
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders
Attitudes of European physicians towards the use of long-acting injectable antipsychotics